

IN THE UNITED STATES COURT OF FEDERAL CLAIMS

	)	
HUMANA INC.,	)	
	)	
Plaintiff,	)	
	)	Case No. 20-996 C
v.	)	
	)	
THE UNITED STATES OF AMERICA,	)	
	)	
Defendant.	)	
	)	

**COMPLAINT**

Humana Inc., on behalf of its aggrieved subsidiaries<sup>1</sup> (“Plaintiff” or “Humana”), by and through its undersigned counsel, files this Complaint against Defendant, the United States of America (“Defendant,” “United States,” or “Government”), and seeks damages and other relief for the Defendant’s (1) violation of Section 1402 of the Patient Protection and Affordable Care Act (“Section 1402”) and 45 C.F.R. § 156.430 to make cost-sharing reduction payments due and owing for benefit year 2017; and (2) breach of its cost-sharing reduction payment obligations under an implied-in-fact contract. In support of this action, Plaintiff states and alleges as follows:

**NATURE OF ACTION**

1. In March 2010, the Government enacted the Patient Protection and Affordable Care Act<sup>2</sup> and the Health Care and Education Reconciliation Act<sup>3</sup> (collectively, the “Affordable

<sup>1</sup> These entities are: Humana Health Plan, Inc. (HIOS ID 15411), Humana Health Plan of Texas, Inc. (HIOS ID 32673), Humana Medical Plan, Inc. (HIOS ID 35783), Humana Health Benefit Plan of Louisiana, Inc. (HIOS ID 44965), Humana Medical Plan of Michigan, Inc. (HIOS ID 46275), Humana Insurance Company (HIOS ID 48963), Humana Insurance Company (HIOS ID 30613), and Humana Health Plan (HIOS ID 58288).

<sup>2</sup> Pub. L. No. 111-148 (Mar. 23, 2010), 124 Stat. 119.

Care Act” or the “Act” or “ACA”).

2. The Act represented a major shift in healthcare regulation and coverage in the country, with the principal objective of making comprehensive and affordable health insurance available to tens of millions of then-uninsured Americans.

3. To accomplish its aims, the ACA ushered in a host of market-wide reforms and requirements affecting the private health insurance industry. Among other things, the Act addressed the scope of covered services, availability of coverage, renewability of coverage, out-of-pocket costs for consumers, pricing, and other coverage determinants. The Act limits health insurance product variation and restricts pricing and underwriting practices. For example, by placing restrictions on the premium spread based on the age of the policy holder, the Act ensures that premiums are based on community rating (*i.e.*, the risk pool posed by the entire community) instead of an assessment of an individual’s health status. The Act also provides for guaranteed issuance of coverage and renewability of coverage.

4. The ACA requires individuals to purchase coverage if they are not otherwise insured, but also created a support system of federal subsidies to offset the costs of coverage. The ACA’s individual mandate, coupled with the availability of federal subsidies, was designed to realize the ACA’s twin goals of increasing both the availability and affordability of health insurance coverage. Together, they dramatically increased the number of individuals—many previously uninsured—purchasing health insurance. To help serve the vastly expanded pool of individuals seeking coverage, the ACA also established health insurance exchanges—online marketplaces where individuals and small groups may purchase health insurance. Created by Title I, Subtitle D of the ACA, the health insurance exchanges “are designed to bring together

---

<sup>3</sup> Pub. L. No. 111-152 (Mar. 30, 2010), 124 Stat. 1029.

buyers and sellers of insurance, with the goal of increasing access to coverage” offered in a competitive marketplace.

5. In order to facilitate affordability and access to competitive health insurance through the exchanges (also referred to as “marketplaces”), Congress encouraged health insurance issuers to offer qualified health plans in the individual and small group markets. A qualified health plan (“QHP”) is a health plan that meets certain standards established by the Centers for Medicare & Medicaid Services (“CMS”) in order to be sold to consumers through the exchanges.

6. Additionally, the ACA requires health plans in the individual and small group markets to cover essential health benefits (“EHBs”).<sup>4</sup> The EHBs are largely an expansion of what was covered pre-ACA. Benefits previously subject to copays or other cost-sharing mechanisms are now mandated to be provided at no cost to the insured, which has made it difficult to predict utilization of these services.

7. The health insurance exchanges presented a new and uncertain risk pool for health insurers. Health insurers considering whether to participate in the exchanges had to confront the uncertainties of pricing health plans for new populations. Insurers had neither sufficient data to accurately predict the needs of the newly insured individuals signing up for plans starting in 2014, nor a model to price with confidence these ACA plans to reflect the medical costs associated with this new and untested marketplace.

---

<sup>4</sup> EHBs include the following ten benefit categories: (1) ambulatory patient services; (2) emergency services; (3) hospitalization; (4) maternity and newborn care; (5) mental health and substance use disorder services including behavioral health treatment; (6) prescription drugs; (7) rehabilitative and habilitative services and devices; (8) laboratory services; (9) preventive and wellness services and chronic disease management; and (10) pediatric services, including oral and vision care.

8. To further the goal of making affordable health insurance available to low- and moderate-income Americans, the ACA established an integrated program of subsidies to defray both the premium expenses and out-of-pocket costs of health insurance with two main components: premium tax credits and cost-sharing reductions.

9. The ACA classifies plans offered on the exchanges into one of four metal levels—silver, gold, platinum, and bronze—based on the actuarial value of the plan. 45 C.F.R. § 156.140. The actuarial value of a plan is determined by “cost-sharing,” *i.e.*, the share of health costs covered, on average, by the plan, taking into account the plan’s deductibles, copayments, coinsurance, and out-of-pocket maximums in a given benefit year<sup>5</sup>. 45 C.F.R. § 156.135; *see also* CBO, *Key Issues in Analyzing Major Health Insurance Proposals* at 15-17 (Dec. 2008), *available at* [www.cbo.gov/publication/41746](http://www.cbo.gov/publication/41746).

10. A “silver” plan is a plan structured so that the insurer pays approximately 70% of the average enrollee’s health care costs, leaving the enrollee responsible for the other 30% through cost sharing. 42 U.S.C. § 18022(d).

11. Section 1402 of the Act requires insurers to provide cost-sharing reductions—CSRs—to individuals enrolled in a silver plan whose household income is below 250% of the federal poverty level. 42 U.S.C. § 18071(c)(2), (f)(2).

12. The Act then requires that the Secretaries of Health and Human Services (“HHS”) and the Treasury “shall make periodic and timely payments to the [QHP] issuer equal to the value of the reductions.” 42 U.S.C. § 18071(emphasis added). These payments are made directly to health insurance issuers as reimbursement for the reductions they will or have provided. *Id.* § 18082(a)(3).

---

<sup>5</sup> A “benefit year” is “a calendar year for which a health plan provides coverage for health benefits.” 45 C.F.R. § 155.20.

13. After making such payments from the inception of the Act, and over a period of 45 months, the Government determined that it lacked an appropriation from which to make the payments. Without a source of funds from which to make the required CSR payments, HHS could not make the required payments. Thus, in an October 12, 2017 memorandum, HHS Acting Secretary Eric Hargan stated that “CSR payments to issuers must stop, effective immediately.”<sup>6</sup> The result is that Plaintiff was not reimbursed for CSR reductions that were due and owing for much of the 2017 benefit year.

14. The statutory guarantee of reimbursement is one of the ACA’s linchpins. If insurers are not compensated by the Government for making the required cost-sharing reductions for eligible individuals enrolled in silver plans as required by the statute, insurers have no ability to adjust premiums mid-year to capture the statutory obligation to pay providers the enhanced coverage of the CSRs. In other words, carriers are left to meet their obligations and the Government’s obligations due to the Government’s refusal to meet its statutory obligations.

15. Consistent with the ACA’s intended mission, Humana and its subsidiaries insure individuals and groups on the Humana Exchanges, in industries that have typically lacked insurance coverage or have been underinsured, on the exchanges.

16. The Government’s failure to pay CSR reimbursements deprives QHP issuers, including Humana, of money to which they are entitled by statute on account of their performance in the exchanges for benefit year 2017. CBO estimated CSR payments of approximately \$7 billion for fiscal year 2017.<sup>7</sup> Regardless of whether Congress appropriated

---

<sup>6</sup> Oct. 12, 2017 Mem. from E. Hargan to S. Verma re Payments to Issuers for Cost-Sharing Reductions (CSRs), *available at* <https://www.hhs.gov/sites/default/files/csr-payment-memo.pdf>

<sup>7</sup> See CBO, Federal Subsidies Under the Affordable Care Act for Health Insurance Coverage Related to the Expansion of Medicaid and Nongroup Health Insurance: Tables from CBO’s (Continued...)

sufficient funds to HHS to make the CSR payments, the Government's statutory obligation to make such payments, and Plaintiff's right to those payments, remains.

17. By this lawsuit, Plaintiff seeks full payment of the CSR payments it is entitled to under the ACA and that the Government currently owes for 2017, in the amount of \$1,957,699.61<sup>8</sup>.

### **JURISDICTION**

18. This Court has jurisdiction over the subject matter of this action pursuant to the Tucker Act, 28 U.S.C. § 1491. The statutory causes of action that give rise to this Court's Tucker Act jurisdiction is Section 1402, a money-mandating statute that requires payment from the federal government to QHP issuers, like Plaintiff, that satisfy certain criteria. Section 156.430 of Title 45, Code of Federal Regulations, is a money-mandating regulation that implements Section 1402, and thus also obligates payment from the federal government to QHP issuers that satisfy certain criteria.

19. In the alternative, the Contract Disputes Act, 41 U.S.C. §§ 7101 *et seq.*, a money-mandating statute, provides Plaintiff a cause of action that gives rise to this Court's jurisdiction pursuant to the Tucker Act.

---

January 2017 Baseline at 4, *available at*

<https://www.cbo.gov/sites/default/files/recurringdata/51298-2017-01-healthinsurance.pdf>.

<sup>8</sup> \$116,834.54 for Humana Health Plan, Inc. (HIOS ID 15411); \$784,769.29 for Humana Health Plan of Texas, Inc. (HIOS ID 32673); \$771,269.46 for Humana Medical Plan, Inc. (HIOS ID 35783); \$49,266.20 for Humana Health Benefit Plan of Louisiana, Inc. (HIOS ID 44965); \$10,752.37 for Humana Medical Plan of Michigan, Inc. (HIOS ID 46275); \$189,113.36 for Humana Insurance Company (HIOS ID 48963); \$24,959.77 for Humana Insurance Company (HIOS ID 30613); and \$10,734.62 for Humana Health Plan (HIOS ID 58288).

20. This controversy is ripe because CMS has failed to pay Plaintiff the full amounts owed for 2017 as required by Section 1402, Section 156.430, and the parties' implied-in-fact contracts.

### **PARTIES**

21. Plaintiff, Humana, is a corporation organized under the laws of Delaware with its principal place of business in Louisville, Kentucky.

22. Humana's subsidiaries operated as QHP issuers on the 15 Humana Exchanges and offered comprehensive health insurance benefits to individuals, families, and businesses.

23. In total, Humana provided insurance coverage through QHPs to over 2 million individuals on and off the exchanges.

24. Humana has aggressively pursued the ACA's goal of connecting the people in its service area to insurance coverage opportunities with the understanding that a broader base of insured is better for the individuals within the pool and the overall functioning of the marketplaces.

25. The defendant is the Government, acting at times through CMS or HHS. Unless otherwise noted, references in this Complaint to CMS include HHS where applicable.

### **FACTUAL ALLEGATIONS**

#### **I. The Affordable Care Act Established a Cost-Sharing Reduction Program with Advance Payment Obligations.**

26. The ACA imposed certain obligations on the federal government to help incentivize the participation of private insurers, stabilize premiums, and induce the uninsured to purchase health insurance coverage. Relevant to this dispute, the ACA established a cost-sharing reduction reimbursement, paid preemptively to certain qualified insurers, to facilitate the core statutory mission of providing affordable health care to low- and moderate-income Americans.

27. Section 1402 of the Affordable Care Act, as codified at 42 U.S.C. § 18071, created the CSR program. In relevant part, that Section states:

(a) IN GENERAL.—In the case of an eligible insured enrolled in a qualified health plan—

(1) the Secretary shall notify the issuer of the plan of such eligibility; and

(2) the issuer *shall reduce* the cost-sharing under the plan at the level and in the manner specified in subsection (c).

[ . . . ]

(c)(3) Methods for Reducing Cost-Sharing

(A) In general. An issuer of a qualified health plan making reductions under this subsection shall notify the Secretary of such reductions and *the Secretary shall make periodic and timely payments to the issuer equal to the value of the reductions.*

*See* 42 U.S.C. § 18071(emphases added).

28. HHS implemented the CSR implemented the CSR payments in the Code of Federal Regulations at 45 C.F.R. § 156.430. In relevant part, Section 156.430 states that “[a] QHP issuer *will receive periodic advance payments* based on the advance payment amounts calculated in accordance with § 155.1030(b)(3) of this subchapter.” (Emphasis added.) Section 155.1030(b)(3) and other regulations set forth the calculation methodologies applicable to CSR payments.

29. Following the ACA’s implementation, the Government established a CSR reimbursement schedule under which the Government would provide the required periodic advance payments to QHP issuers. *See* 42 U.S.C. § 18082; 45 C.F.R. § 156.430(b)-(d). The reimbursements are then periodically reconciled to the actual amount of cost-sharing reductions made to enrollees and providers. 45 C.F.R. § 156.430(c). Specifically, CMS established “a payment approach under which HHS would make monthly advance payments to issuers to cover

projected cost-sharing reduction amounts, and then reconcile those advance payments at the end of the benefit year to the actual cost-sharing reduction amounts.”<sup>9</sup> “After the close of the benefit year, QHP issuers must submit to HHS information on the actual value of the cost-sharing reductions provided” and HHS “would then reconcile the advance payments and the actual cost-sharing reduction amounts.”<sup>10</sup> This reconciliation process also involves a “restatement” submission where QHP issuers recalculates and restates “all claims for the associated policy as necessary using the standard CMS methodology and associated guidance prior to a final re-adjudication of such claims for reconciliation.”<sup>11</sup> Finally, the Government would reimburse the QHP issuer “any amounts necessary to reflect the CSR provided or, as appropriate, the issuer [would] be charged for excess amounts paid to it.”<sup>12</sup>

## **II. QHP Issuers Participated on Exchanges and Set Prices in Reliance on the Cost-Sharing Reduction Payments.**

30. For QHP issuers to participate on the marketplaces for the 2017 benefit year, they had to submit their premiums to the appropriate state or federal regulatory authority during May 2016 and submit a signed Qualified Health Plan Issuer Agreement (“QHPIA”) to CMS by the

---

<sup>9</sup> CMS, HHS Notice of Benefit and Payment Parameters for 2014 (Mar. 11, 2013), at 7, *available at* <https://www.cms.gov/CCIIO/Resources/Files/Downloads/payment-notice-technical-summary-3-11-2013.pdf>.

<sup>10</sup> *Id.*

<sup>11</sup> CMS, Manual for Reconciliation of the Cost-Sharing Reduction Component of Advance Payments for Benefit Year 2017 (March 29, 2018), at 9, *available at* <https://www.cms.gov/CCIIO/Resources/Forms-Reports-and-Other-Resources/Downloads/Final-CSR-Reconciliation-Guidance-BY2017.pdf>.

<sup>12</sup> CMS, Manual for Reconciliation of the Cost-Sharing Reduction Component of Advance Payments for Benefit Years 2014 and 2015 (Mar. 16, 2016), at 28, *available at* [https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/CMS\\_Guidance\\_on\\_CSR\\_Reconciliation-for\\_2014\\_and\\_2015\\_benefit\\_years.pdf](https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/CMS_Guidance_on_CSR_Reconciliation-for_2014_and_2015_benefit_years.pdf); *see also* 45 C.F.R. 156.430(e).

end of September 2016.<sup>13</sup> Humana timely submitted a signed QHPIA, and by doing so committed itself to offering health insurance coverage on the exchange for benefit year 2017. Because the QHPIA has limited termination rights, and because terminating the QHPIA under any circumstance does not obviate the issuer’s obligations under state law to continue coverage for enrollees who purchased the plan, Humana’s commitment to the 2017 marketplace was effectively irrevocable as of the end of September 2016.<sup>14</sup>

31. Humana committed itself to participating in the marketplace in 2017 with the express understanding—based on the plain text of Section 1402 and the Government’s actions in previous benefit years—that, for those plans that required the issuers to reduce cost-sharing obligations of the enrollee, the Government would honor the statutory mandate, *i.e.*, “***the Secretary shall make periodic and timely payments to the issuer equal to the value of the reductions.***” And in fact, in accordance with that understanding, the Government made monthly advance payments from January 2014 up and until October 2017. It was not until October 12, 2017—over a year after Humana had committed itself irrevocably to the 2017 exchange—that the Government first announced that it would not make CSR payments for the remainder of the 2017 benefit year.

### **III. Appropriations for Cost-Sharing Reduction Reimbursements**

32. Section 1401 of the ACA added a new section to the Internal Revenue Code that provided eligible insureds with premium tax credits to cover their health insurance premiums. 26 U.S.C. § 36B. The ACA also amended 31 U.S.C. § 1324, which establishes a permanent

---

<sup>13</sup> CMS, Key Dates for Calendar Year 2016: QHP Certification in the Federally-facilitated Marketplaces; Rate Review; Risk Adjustment and Reinsurance (Dec. 23, 2015), *available at* <https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/Final-2016-key-dates-table-April-2016.pdf>.

<sup>14</sup> *See* 45 C.F.R. § 147.106(b).

appropriation of “[n]ecessary amounts . . . for refunding internal revenue collections as provided by law,” including “refunds due from” specified provisions of the tax code. 31 U.S.C. § 1324. Specifically, Section 1401 of the ACA amended the list in Section 1324 to include “refunds due from” Section 36B. 26 U.S.C. § 36B. Until October 2017, the Government relied on the appropriation in Section 1324 to pay amounts owed under both Sections 1401 and 1402.

33. In its April 2013 budget request to Congress for fiscal year 2014, the Office of Management and Budget (“OMB”) included a request for a line-item appropriation designating funds for the payment of cost-sharing reductions. *See* Fiscal Year 2014 Budget of the United States Government, Appendix at 448 (Apr. 10, 2013). The same day, HHS separately submitted its justification to Congressional Appropriations committees stating that “CMS requests an appropriation in order to ensure adequate funding to make payments to issuers to cover reduced cost-sharing in FY 2014.” *See* HHS, Fiscal Year 2014, CMS, Justification of Estimates for Appropriations Committees at 184 (Apr. 10, 2013).

34. Congress did not provide the line-item appropriation requested by HHS. *See* S. Rep. No. 113-71, 113th Cong. at 123 (July 11, 2013). Congress never repealed or amended the CSR provision, however, and the October 2013 legislation references the existence of CSR reimbursements. *See* Continuing Appropriations Act, 2014, Pub. L. No. 113-46, Div. B, § 1001(a), 127 Stat. 558, 566 (Oct. 17, 2013) (requiring HHS to certify that a program was in place to verify that applicants were eligible for “premium tax credits . . . and reductions in cost-sharing” before “making such credits and reductions available”).

35. In January 2014, HHS began making monthly advance payments to reimburse

QHP issuers for cost-sharing reductions,<sup>15</sup> relying on Section 1324 as the appropriation for these payments.<sup>16</sup>

36. Congress has never included any language in appropriations or other bills preventing HHS, CMS, or the Treasury from accessing certain funds or accounts to make CSR payments.

#### **IV. Legal Challenge By House of Representatives**

37. On November 21, 2014, the U.S. House of Representatives (the “House”) filed a complaint against HHS and the Treasury, in which it sought an injunction preventing the executive branch from “making any further Section 1402 Offset Program payments to Insurers unless and until a law appropriating funds for such payments is enacted.” *See* Compl. ¶ 27, *House v. Burwell*, Case No. 1:14-cv-01967-RMC, Dkt. 1 (D.D.C. filed Nov. 21, 2014). In its complaint, the House argued that “Congress has not, and never has, appropriated any funds (whether through temporary appropriations or permanent appropriations) to make any Section 1402 Offset Program payments to Insurers.” *Id.* ¶ 28. The Government moved for summary judgment, asserting that 31 U.S.C. § 1324 provided a permanent appropriation for both Section 1401 premium tax credits and Section 1402 CSR reimbursements. *See* Defs.’ Mem. ISO Mot. for Summ. J., *House v. Burwell*, Case No. 1:14-cv-01967-RMC, Dkt. 55-1 (D.D.C. Dec. 2, 2015)

---

<sup>15</sup> *See* CMS, Manual for Reconciliation of the Cost-Sharing Reduction Component of Advance Payments for Benefit Years 2014 and 2015 (Mar. 16, 2016), at 27 (“Payments to issuers of estimated monthly amounts began in January 2014.”), *available at* [https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/CMS\\_Guidance\\_on\\_CSR\\_Reconciliation\\_for\\_2014\\_and\\_2015\\_benefit\\_years.pdf](https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/CMS_Guidance_on_CSR_Reconciliation_for_2014_and_2015_benefit_years.pdf).

<sup>16</sup> *See* Letter from Sylvia M. Burwell, Dir., OMB, to Senators Ted Cruz and Michael S. Lee, at Responses p. 4 (May 21, 2014), (“cost-sharing subsidy payments are being made through the advance payments program and will be paid out of the same account from which the premium tax credit portion of the advance payments for that program are paid”), *available at* [http://www.cruz.senate.gov/files/documents/Letters/20140521\\_Burwell\\_Response.pdf](http://www.cruz.senate.gov/files/documents/Letters/20140521_Burwell_Response.pdf).

at 11.<sup>17</sup> The district court ruled in favor of the House and entered an injunction preventing any further reimbursements under Section 1402, but stayed the injunction pending resolution of any appeal. *House v. Burwell*, 185 F. Supp. 3d 165 (D.D.C. 2016).

38. The Government appealed the ruling to the D.C. Circuit. In November 2016, the House asked the Court of Appeals to hold the case in abeyance to “provide the President-Elect and his future Administration time to consider whether to continue prosecuting or to otherwise resolve this appeal.” Appellee’s Mot. to Hold Briefing in Abeyance, *House v. Burwell*, Case No. 16-5202, Dkt. No. 1647228 (D.C. Cir. Nov. 21, 2016) at 1-2. The D.C. Circuit granted the request and the appeal remained in abeyance until Friday, December 15, 2017, when the parties announced that they had reached a settlement providing for the parties to request that district court’s decision case to be vacated. On May 16, 2018, the D.C. Circuit granted the motion for remand to vacate the Court’s injunction on HHS’s CSR payments. On May 16, 2018, the D.C. Circuit granted the motion for remand to vacate the district court’s injunction on HHS’s CSR payments, and the district court accordingly vacated its ruling two days later.

#### **V. The Government’s Newly Announced Refusal to Reimburse CSRs**

39. Although the Government continued to make CSR reimbursements for most of 2017, it decided in October 2017 to stop doing so, positing that 31 U.S.C. § 1324 could not be used to fund CSR reimbursements. The Department of Justice concluded that Section 1401 premium tax credits and Section 1402 CSR reimbursements were two distinct programs, and the

---

<sup>17</sup> In its summary judgment briefing papers, the Government expressly acknowledged that the ACA “requires the government to pay cost-sharing reductions to issuers” and that “[t]he absence of an appropriation would not prevent the insurers from seeking to enforce that statutory right through litigation.” Defs.’ Mem. ISO Mot. for Summ. J., *House v. Burwell*, Case No. 1:14-cv-01967-RMC, Dkt. 55-1 (D.D.C. Dec. 2, 2015) at 20. Moreover, the Government acknowledged that prevailing insurers “can receive the amount to which it is entitled from the permanent appropriation Congress has made in the Judgment Fund . . . . The mere absence of a more specific appropriation is not necessarily a defense to recovery from that Fund.” *Id.*

permanent appropriation in Section 1324 only provided funding for the Section 1401 premium tax credits. *See* Oct. 11, 2017 Ltr. from Att. Gen. Sessions to Secretary of Treasury and Acting Secretary of HHS. The next day, HHS announced that it would stop making CSR reimbursements “until a valid appropriation exists.” Oct. 12, 2017 Mem. from E. Hargan to S. Verma re Payments to Issuers for Cost-Sharing Reductions (CSRs).

**VI. Plaintiff Has Suffered Substantial Harm as a Result of The Government’s Refusal to Pay Amounts Owed.**

40. Humana promotes expansive benefits coverage and superb quality in its health care model and has provided coverage to traditionally underserved populations.

41. QHP issuers are required by state and federal regulations to set their ACA-related health insurance rates well before the year they become effective. These unreimbursed costs are enormous. The CBO estimated that CSR reimbursements to QHP issuers would be \$7 billion in fiscal year 2017, \$10 billion in 2018, and rise to \$16 billion by 2027.<sup>18</sup> An April 2017 study analyzing the potential effect of ending CSR reimbursements predicted that “[m]any insurers might react to the end of subsidy payments by exiting the ACA marketplaces. If insurers choose to remain in the marketplaces, they would need to raise premiums to offset the loss of the payments.”<sup>19</sup>

42. As an October 13, 2017 joint statement from America’s Health Insurance Plans and Blue Cross and Blue Shield Association noted, the decision to end CSR reimbursements has

---

<sup>18</sup> *See* CBO, Federal Subsidies Under the Affordable Care Act for Health Insurance Coverage Related to the Expansion of Medicaid and Nongroup Health Insurance: Tables from CBO’s January 2017 Baseline at 4, *available at* <https://www.cbo.gov/sites/default/files/recurringdata/51298-2017-01-healthinsurance.pdf>.

<sup>19</sup> Larry Levitt, Cynthia Cox, and Gary Claxton, *The Effects of Ending the Affordable Care Act’s Cost-Sharing Reduction Payments*, Kaiser Family Foundation, Apr. 25, 2017, *available at* <https://www.kff.org/health-reform/issue-brief/the-effects-of-ending-the-affordable-care-acts-cost-sharing-reduction-payments/>.

“real consequences,” including that “[c]osts will go up and choices will be restricted.”<sup>20</sup> These effects are currently playing out in every major ACA exchange across the country.

43. Humana is not immune to these harms, and in fact has already suffered, and will continue to suffer, their effects. Like other QHP issuers, Humana was owed monthly CSR reimbursements in October 2017, November 2017, and December 2017 that have not been paid. Pursuant to the calculation methodologies in Section 155.1030(b)(3) and other applicable regulations, Humana is owed \$1,957,699.61 in unpaid CSR reimbursements for benefit year 2017. Like other QHP issuers, Humana is still required by law to provide cost-sharing reductions to eligible insureds, despite not receiving the mandated reimbursement from the Government. This has caused Humana to suffer large financial losses. It also leads to instability in the insurance markets and hinders Humana’s ability to design and price plans effectively for the ACA exchanges.

## **CLAIMS FOR RELIEF**

### **COUNT I**

#### **(Violation of Statutory and Regulatory Mandate to Make Payments)**

44. Plaintiff realleges and incorporates the preceding paragraphs as if fully set forth herein.

45. As part of its obligations under Section 1402 of the ACA and/or its obligations under Section 156.430, the Government is required to pay any eligible QHP the applicable cost-sharing reductions mandated by the ACA.

46. Plaintiff is an eligible QHP issuer under the ACA, and based on its adherence to

---

<sup>20</sup> Kristine Grow, *Health Plans Issue Joint Statement Regarding Funding for Cost-Sharing Reduction Benefits for Millions of Americans*, American Health Insurance Plans (AHIP), Oct. 13, 2017, available at <https://www.ahip.org/joint-statement-regarding-funding-for-crs/>.

the ACA and its notification of cost-sharing reduction amounts to CMS, satisfied the requirements for payment from the Government under Section 1402 of the ACA and Section 156.430.

47. The Government has failed to perform as it is obligated under Section 1402 of the ACA and Section 156.430, and has affirmatively stated that it will not satisfy those obligations as required by the statute.

48. The Government's failure to provide timely payments to Plaintiff is a violation of Section 1402 of the ACA and Section 156.430, and Plaintiff estimates that it has suffered \$1,957,699.61 in damages in payments for benefit year 2017 as a result of the Government's actions.

## COUNT II

### **(Breach of Implied-In-Fact Contract to Make Payments)**

49. Plaintiff realleges and incorporates the preceding paragraphs as if fully set forth herein.

50. Plaintiff entered into a valid implied-in-fact contract with the Government regarding the Government's obligation to make full and timely CSR payments to Plaintiff in exchange for its agreement to become a QHP issuer and participate in the health care exchanges.

51. Section 1402 of the ACA, HHS's implementing regulations, the Government's actions in making CSR payments for benefit years 2014, 2015, 2016, and nine months of 2017, and the actions of agency officials with authority to bind the Government regarding their obligation to make CSR payments constitute a clear and unambiguous offer by the Government to make full and timely CSR payments to health insurers, including Plaintiff, that agreed to participate as QHP issuers in the ACA marketplaces. This offer evidences a clear intent by the

Government to contract with Plaintiff.

52. Plaintiff accepted the Government's offer by agreeing to become a QHP issuer, accepting the obligations, responsibilities, and conditions the Government imposed on QHP issuers under the ACA and proceeding to provide health insurance on the health care exchanges. Plaintiff satisfied and complied with its obligations and conditions that existed under the implied-in-fact contract.

53. The Government's agreement to make full and timely CSR payments was a significant factor material to Plaintiff's decision to participate in the health care exchanges.

54. The parties' mutual intent to contract is further confirmed by the parties' conduct, performance, and statements following Plaintiff's acceptance of the Government's offer, and the Government's repeated assurances that full and timely CSR payments would be made.

55. The implied-in-fact contract was also supported by mutual consideration: the CSR's reimbursement to alleviate the financial requirement that QHP issuers were forced to bear under the ACA was a critical consideration that significantly influenced Plaintiff's decision to become a QHP issuer and participate in the exchanges. Plaintiff, in turn, provided a real benefit to the Government by agreeing to become a QHP issuer and participating in the exchanges, as adequate insurer participation was crucial to the Government achieving the overarching goal of the ACA exchange programs—to guarantee the availability of affordable, high-quality health insurance coverage for all Americans by protecting consumers from increases in premiums.

56. The Government induced Plaintiff to participate in the health care exchanges in part by including the CSR payments in Section 1402 of the ACA and its implementing regulations, by which the Government committed to make health insurers whole financially for the mandated cost-sharing reductions.

57. The Government repeatedly acknowledged its commitments to provide financial assistance to QHP issuers and its obligations to make full and timely CSR payments to qualifying issuers through its conduct and statements to the public and to Plaintiff, made or ratified by representatives of the Government who had express or implied actual authority to bind the Government.

58. The Government's failure to make full and timely CSR payments to Plaintiff is a material breach of the implied-in-fact contract, and Plaintiff has suffered damages estimated to be \$1,957,699.61 for benefit year 2017.

**PRAYER FOR RELIEF**

Plaintiff requests the following relief:

A. That the Court award Plaintiff \$1,957,699.61, the amount to which Plaintiff estimates that it is entitled under Section 1402 of the Affordable Care Act and Section 156.430;

B. That the Court award pre-judgment and post-judgment interest at the maximum rate permitted under the law;

C. That the Court award such court costs, litigation expenses, and attorneys' fees as are available under applicable law; and

D. That the Court award such other and further relief as the Court deems proper and just.

Dated: August 10, 2020

OF COUNSEL:  
Daniel Wolff  
Skye Mathieson  
Charles Baek

CROWELL & MORING LLP

Respectfully submitted,

/s/ Stephen McBrady  
Stephen McBrady  
CROWELL & MORING LLP  
1001 Pennsylvania Avenue, NW  
Washington, DC 20004  
Tel: (202) 624-2500

1001 Pennsylvania Avenue, NW  
Washington, DC 20004  
Tel: (202) 624-2500

Fax: (202) 628-5116  
SMcBrady@crowell.com

*Counsel for Humana Inc.*

**CERTIFICATE OF SERVICE**

I certify that on August 10, 2020, a copy of the forgoing Complaint was filed electronically using the Court's Electronic Case Filing (ECF) system. I understand that notice of this filing will be served on Defendant's Counsel via the Court's ECF system.

/s/ Stephen McBrady  
Stephen McBrady  
CROWELL & MORING LLP  
1001 Pennsylvania Avenue, NW  
Washington, DC 20004  
Tel: (202) 624-2500  
Fax: (202) 628-5116  
SMcBrady@crowell.com